ConductScience.org, home

Comparison · NCT02060903-5feb49c3

Abametapir Lotion 0.74% w/w vs Vehicle Lotion: Proportion of Index Subjects Who Are Lice-free at All Follow-up Visits Through to the Day 14 Visit.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Abametapir Lotion 0.74% w/w vs Vehicle Lotion: Proportion of Index Subjects Who Are Lice-free at All Follow-up Visits Through to the Day 14 Visit. Trial comparisons, record NCT02060903-5feb49c3. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02060903-5feb49c3

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.8110.6860.894wilson
Risk in group 20.5090.3810.636wilson
Risk difference, group 1 minus group 20.3020.1240.455newcombe hybrid score
Risk ratio, group 1 over group 21.591.192.13log
Odds ratio, group 1 over group 24.151.749.87log
Number needed to treat, for one more participant with the outcome on Abametapir Lotion 0.74% w/w than on Vehicle Lotion3.312.28.06from the risk difference interval

Groups2

Group 2 names the comparator: vehicle.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Abametapir Lotion 0.74% w/wSingle topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.~Abametapir Lotion 0.74% w/w4353OG000
Group 2Vehicle LotionSingle topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.~Vehicle Lotion2855OG001

Outcome

Type
PRIMARY
Title
Proportion of Index Subjects Who Are Lice-free at All Follow-up Visits Through to the Day 14 Visit.
Description
Proportion of index subjects randomized into the study who are lice free at all follow up visits through to the Day 14 visit. The index subject of a household was the youngest person within that household with at least 3 live lice present, as assessed over a period of up to 15 minutes at the Screening Visit.
Time frame
14 days
Population
The ITT population consisted of all 108 index subjects who were enrolled and randomized in the study.

Source ClinicalTrials.gov

Trial

Title
A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation
NCT number
NCT02060903
Phases
PHASE3
Conditions
Head Lice Infestation
Interventions
Abametapir Lotion 0.74% w/w, Vehicle Lotion
Lead sponsor
Dr. Reddy's Laboratories Limited
Results first posted
2020-09-23

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02060903-5feb49c3